Injectable Drug Delivery Market (By Type: Devices, Formulations; By Formulation Packaging: Ampules, Vials, Cartridges, Bottles; By Therapeutic Application: Auto-immune diseases. Hormonal Disorders, Orphan Diseases, Oncology, Other Therapeutic Applications; By Usage Pattern: Curative Care, Immunization, Other Usage Pattern; By Site of Administration, By Distribution Channel; By Facility of Use) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030


The global injectable drug delivery market size was valued at US$ 561.06 billion in 2021 and is expected to hit US$ 1,223.6 billion by 2030 with a CAGR of 9.05% from 2022 to 2030.

Injectable Drug Delivery Market Size 2021 to 2030

Ket Takeway:

  • North America has accounted 45% revenue share in 2021.
  • By device type, the prefilled syringes segment has held market share of over 58% in 2021 and it is growing at a CAGR of 9.5% over the forecast period.
  • By therapeutic application, the oncology segment has held highest revenue share 44% in 2021.
  • By distribution channel, the hospitals and clinics segment has captured market share of around 61% in 2021.

Growth Factors

One of the significant factors driving the growth of global injectable drug delivery market is growing prevalence of cancer. According to the International Agency for Research on Cancer, 1 in 5 individuals will develop cancer throughout their lifetime by December 2020, with 1 in 8 men and 1 in 11 women dying from the disease worldwide. As per the International Agency for Research, global cancer cases and deaths will increase to 19.3 million cases and 10 million deaths in 2020, up from 18 million cases and deaths in 2018. In addition, the key market players are concentrating on new product development and launches. For example, the U.S. Food and Drug Administration authorized Apretude for pre-exposure prophylaxis to lower the risk of sexually acquired HIV in adults weighing at least 35 kg in December 2021.

The COVID-19 epidemic has had both beneficial and negative consequences on the healthcare sector. The expanding COVID-19 patient population is putting strain on healthcare systems. Due to increased demand for medical goods such as pre-filled syringes and injections, manufacturers have increased their production capacity to keep up with demand. Furthermore, the government all around the world is contributing towards the growth of global injectable drugs delivery market. The government is heavily investing for the development and launch of novel injectable drugs delivery in the market.

Due to the broad product portfolio and impressive distribution network of large businesses in both emerging and established nations, the competitive rivalry of the global injectable drugs delivery market is unified in nature. Some of the primary strategies followed by major market players include the significant funding for the development of innovative and latest technologies, as well as the introduction of unique goods such as sophisticated wearable medical devices and gadgets.

Report Scope of the Infant Injectable Drug Delivery Market

Report Coverage Details
Market Size by 2030 USD 1,223.6 Billion
Growth Rate from 2022 to 2030

CAGR of 9.05%

Largest Market North America 
Fastest Growing Market Europe
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, Geography
Companies Mentioned Becton, Dickinson and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Baxter International, Inc., Sandoz, Terumo, Schott AG, Gerresheimer, Ypsomed, Bespak, B. Braun Melsungen


Type Insights

The devices segment accounted largest revenue share in 2021. The growing prevalence of chronic disorders is leadingto an increase in overall syringe practice, predominantly disposable syringes. The cardiovascular illnesses, diabetes, and obesity have been found to be leading causes of death from chronic disorders. As populacesurge is believed to be the critical factor in emerging nations, this is likely to have the highest impact all around the world.

Injectable Drugs Delivery Market Share, By Type, 2021 (%)

The formulations segment is fastest growing segment of the injectable drugs delivery market in 2021. The growing prevalence of chronic disorders, increased acceptance of self-injection, patient adherence, biologics, and innovative technologies are all factors driving this segment’s rapid rise.

Therapeutic Application Insights

The auto-immune diseases segment accounted revenue share in 2021. The immune system attacks and destroys its own body tissue in autoimmune diseases. The diabetes, lupus, rheumatoid arthritis, and other auto-immune diseases are among the most frequent. Immune suppressants, anti-inflammatory medicines, and other medications have been licensed to treat auto-immune illness.

The oncology segment is fastest growing segment of the injectable drugs delivery market in 2020. The growing prevalence of cancer is driving the growth of the segment. As per the American Cancer Society, by 2020, there will be roughly 1,806,590 cancer patients in the U.S. alone, up 31% from 2010.

Distribution Channel Insights

The hospitals segment dominated the injectable drugs delivery market in 2021. This is attributed to an increase in the number of people admitted to hospitals with acute and chronic wounds. In addition, expansion of the segment is also being driven by the surge in the number of standalone clinics in established and developing nations.

Injectable Drugs Delivery Market Share, By Distribution Channel, 2021 (%)

The retail pharmacy stores segment is expected to strong growth over the forecast period. The retail pharmacy stores sell pharmaceutical medications and drugs. These stores offer generic and branded medications, as well as other pharmaceutical supplies. The growing preference of patients for buying injectable drugs delivery from these stores is driving the growth of the segment. In addition, growing consumption of over the counter drugs is also contributing towards the expansion of the retail pharmacy stores segment.

Region Insights

North America dominated the injectable drugs delivery market in 2021. The growth of injectable drugs delivery market in North America region is being attributed to the growing prevalence of various disorders. According to the Alzheimer’s Association, about 6.2 million Americans aged 65 and older will have Alzheimer’s disease by 2020. There are 3.8 million women and 2.4 million men among them. In addition, rising adoption of strategies by market players are also supporting the growth of North America injectable drugs delivery market. Piramal Critical Care teamed with Medivant Healthcare, a pharmaceutical outsourcing facility based in the U.S., in July 2020 to solve the significant shortage of injectable medications in hospitals across the country.

Europe, on the other hand, is expected to develop at the fastest rate during the forecast period. The UK dominates the injectable drugs delivery market in Europe region. The Europe injectable drugs delivery market is attributed to the factors such as the rise of the biologics market, rising incidence of chronic disorders, and the rising demand for self-injection devices are all contributing to this trend. The other factors propelling the growth of injectable drugs delivery market in Europe region are rising disposable income, rising number of partnerships, and rising awareness about safety and comfort.

Key Developments

  • BD bought CareFusion Corporation in March 2015 to broaden its capabilities and improve drug management and patient safety. In the same year, BD purchased CRISI Medical Systems, a medical technology business, in order to improve the efficiency of drug delivery via IV injectables. BD has a worldwide presence in 50 nations, allowing it to maintain its position in the global market.
  • Pfenex Inc. announced in June 2020 that Alvogen, its commercialization partner, had introduced Teriparatide Injection in the U.S. for a variety of indications, including postmenopausal women with osteoporosis who are at high risk of broken bones.
  • Terumo Corporation teamed up with Ypsomed Group in 2014. The organization combined their prefillable polymer syringe, PLAJEX, with YpsoMate as a result of this agreement. This aided the corporation in strengthening their syringe product offerings.
  • Sanford-Burnham Medical Research Institute and Eli Lilly and Company formed a partnership in 2015 to explore immunological therapeutics for inflammatory bowel disorder, lupus, and autoimmune diseases. The expertise of both institutions will be pooled to discover novel treatments for these disorders. 

Some of the prominent players in the global injectable drugs delivery market include:

  • Becton
  • Dickinson and Company
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Eli Lilly and Company
  • Baxter International, Inc.
  • Sandoz
  • Terumo
  • Schott AG
  • Gerresheimer
  • Ypsomed
  • Bespak
  • B. Braun Melsungen

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Type

  • Devices
    • Conventional Injectables
    • Pre-Filled Syringes
    • Auto-Injectors
    • Pen-Injectors
  • Formulations

By Formulation Packaging

  • Ampules
  • Vials
  • Cartridges
  • Bottles

By Therapeutic Application

  • Auto-immune diseases
  • Hormonal Disorders
  • Orphan Diseases
  • Oncology
  • Others

By Usage Pattern

  • Curative Care
  • Immunization
  • Other

By Site of Administration

  • Skin
  • Circulatory/Musculoskeletal
  • Organs
  • Central Nervous System

By Distribution Channel

  • Hospitals & Clinics
  • Retail Pharmacy Stores
  • Others

By Facility of Use

  • Hospitals & Clinics
  • Home Care Settings
  • Other

 By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of injectable drug delivery market?
The global injectable drug delivery market size was reached at USD 561.06 billion in 2021 and it is expected to rake around USD 1,223.6 billion by 2030.
What will be the CAGR of global injectable drug delivery market?
The global injectable drug delivery market is expected to drive growth at a CAGR of 9.05% from 2022 to 2030.
Who are the major players operating in the injectable drug delivery market?
The major players operating in the injectable drug delivery market are Becton, Dickinson and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Baxter International, Inc., Sandoz, Terumo, Schott AG, Gerresheimer, Ypsomed, Bespak, B. Braun Melsungen
Which are the growth factors of the injectable drug delivery market?
One of the significant factors driving the growth of global injectable drug delivery market is growing prevalence of cancer.
Which region will lead the global injectable drug delivery market?
North America region will lead the global injectable drug delivery market over the forecast period 2022 to 2030.
  • Report Code:1760
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Status:Published

PROCEED TO BUY

   USD 4900
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample